Navigation Links
InterMune to Present at Deutsche Bank Biotech Boston Confab
Date:11/7/2008

BRISBANE, Calif., Nov. 7 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that Daniel G. Welch, Chairman, Chief Executive Officer and President of InterMune, will present at Deutsche Bank's 2008 Biotech Boston Confab on November 11, 2008 at 4:00 p.m. EST.

To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at http://www.intermune.com. The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a research and development portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
2. InterMune to Release Third Quarter 2008 Financial Results on November 6
3. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
4. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
5. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
6. InterMune to Present at Canaccord Adams Conference
7. InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
8. InterMune to Present at BMO Healthcare Conference
9. InterMune to Release Second Quarter 2008 Financial Results and Provide Business Update on July 31
10. InterMune to Present at Jefferies Healthcare Conference
11. InterMune to Present at Goldman Sachs Healthcare and Needham & Co. Biotechnology and Medical Technology Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... April 21, 2017 , ... The University of ... round funding to three startups through the UConn Innovation Fund. The $1.5 million ... startups affiliated with UConn. , The UConn Innovation Fund provides investments of up ...
(Date:4/21/2017)... ... , ... Frederick Innovative Technology Center, Inc. (FITCI), a business ... earned a $77,518 grant from the Rural Maryland Council (RMC) to support refurbishment ... first incubator. A non-profit corporation, FITCI is a public-private partnership of the governments ...
(Date:4/20/2017)... BARBARA, CALIFORNIA (PRWEB) , ... April 20, 2017 , ... ... optimization firm for the life sciences and healthcare industries, is pleased to announce ... the new established USDM subsidiary “USDM Europe GmbH” based in Germany. , Braemer ...
(Date:4/20/2017)... Woburn, MA (PRWEB) , ... April 20, 2017 ... ... high brightness light sources for advanced technology applications, announced today that Chief Executive ... Board (NAAB). , SEMI is the global industry association connecting the ...
Breaking Biology Technology:
(Date:3/22/2017)... , March 21, 2017 Vigilant Solutions ... serving law enforcement agencies, announced today the appointment of ... director of public safety business development. Mr. ... enforcement experience, including a focus on the aviation transportation ... most recent position, Mr. Sheridan served as the Aviation ...
(Date:3/20/2017)... , March 20, 2017 PMD Healthcare announces ... spirometer and Wellness Management System (WMS), a remote, real-time ... in 2010, PMD Healthcare is a Medical Device, Digital ... mission dedicated to creating innovative solutions that empower people ... that intent focus, PMD developed the first ever personal ...
(Date:3/13/2017)... -- Future of security: Biometric Face Matching software  ... ... Face Matching enables to match face pictures against each other or against large ... Identification Systems) ... is the fastest software for biometric Face Matching on the market. The speed ...
Breaking Biology News(10 mins):